ID   PC-9/R
AC   CVCL_S750
SY   PC-9R; PC-9/ER; PC-9ER
DR   cancercelllines; CVCL_S750
DR   Cosmic; 1890454
DR   Cosmic; 2015225
DR   Wikidata; Q54938502
RX   PubMed=21734175;
RX   PubMed=22773810;
RX   PubMed=23733853;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib.
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Unspecified; Note=Acquired during resistance selection process (PubMed=22773810).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_B260 ! PC-9
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 05-10-23; Version: 18
//
RX   PubMed=21734175; DOI=10.1126/scitranslmed.3002356;
RA   Chmielecki J., Foo J., Oxnard G.R., Hutchinson K., Ohashi K.,
RA   Somwar R., Wang L., Amato K.R., Arcila M.E., Sos M.L., Socci N.D.,
RA   Viale A.J., de Stanchina E., Ginsberg M.S., Thomas R.K., Kris M.G.,
RA   Inoue A., Ladanyi M., Miller V.A., Michor F., Pao W.;
RT   "Optimization of dosing for EGFR-mutant non-small cell lung cancer
RT   with evolutionary cancer modeling.";
RL   Sci. Transl. Med. 3:90ra59.1-90ra59.10(2011).
//
RX   PubMed=22773810; DOI=10.1073/pnas.1203530109;
RA   Ohashi K., Sequist L.V., Arcila M.E., Moran T., Chmielecki J.,
RA   Lin Y.-L., Pan Y.-M., Wang L., de Stanchina E., Shien K., Aoe K.,
RA   Toyooka S., Kiura K., Fernandez-Cuesta L., Fidias P., Yang J.C.-H.,
RA   Miller V.A., Riely G.J., Kris M.G., Engelman J.A., Vnencak-Jones C.L.,
RA   Dias-Santagata D., Ladanyi M., Pao W.;
RT   "Lung cancers with acquired resistance to EGFR inhibitors occasionally
RT   harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or
RT   MEK1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:E2127-E2133(2012).
//
RX   PubMed=23733853; DOI=10.1101/gr.152322.112;
RA   Jia P.-L., Jin H.-L., Meador C.B., Xia J.-F., Ohashi K., Liu L.,
RA   Pirazzoli V., Dahlman K.B., Politi K., Michor F., Zhao Z.-M., Pao W.;
RT   "Next-generation sequencing of paired tyrosine kinase
RT   inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines
RT   identifies spectrum of DNA changes associated with drug resistance.";
RL   Genome Res. 23:1434-1445(2013).
//